TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02562144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cutaneous placebo before intravenous cannulation.
Study: NCT02039544
Drug: Xuebi formula
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02039544
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00444262
Drug: VOLUVEN and others solute
Approvals — FDA: no, EMA: no, PMDA: no
Description: VOLUVEN and others solute
Study: NCT02530788
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the evening before operation the patient receives the first dosage of placebo orally as a pill.~After induction of anaesthesia and before being put on the heart-lung-machine the patient receives placebo intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets placebo intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives placebo intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD).
Study: NCT00947323
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 20 daily for six months.
Study: NCT00947323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00446940
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04429802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered
Study: NCT01472614
Drug: DLBS3233
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment will be DLBS3233 at a dose of 100 mg once daily (for 12 weeks) in addition to current anti-diabetic treatment used by respective study subjects and treatment intensification (lifestyle modification)
Study: NCT00005824
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03625453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: 8 weeks with daily administration
Study: NCT01773876
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution of sodium chloride 0.9% 100 ml for intravenous infusion infusion over 24 hours for 14 days discontinuation of placebo if proven invasive candidiasis
Study: NCT01413022
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01413022
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02353871
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A solution containing only the excipients of BTX-A-HAC NG (identical in appearance to the active product). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
Study: NCT00841230
Drug: Lactose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose used as placebo
Study: NCT01278108
Drug: GLPG0778
Approvals — FDA: no, EMA: no, PMDA: no
Description: single ascending doses, oral solution (10 to 800 mg/dose) and capsules (100 mg/dose)
Study: NCT01278108
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, oral solution or capsule (matching corresponding study medication)
Study: NCT01278108
Drug: GLPG0778
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, capsule, 7 days
Study: NCT01278108
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, capsule, 7 days
Study: NCT00456417
Drug: 123-I MNI-187 Injection and Imaging Procedures
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02690337
Drug: DS-1123
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: starting intravenous (IV) dose of 0.1 mg/kg.
Study: NCT04631588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) injection
Study: NCT02140346
Drug: RV1729 matching placebo 28 day repeat dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of repeat doses
Study: NCT00136682
Drug: patient-controlled intravenous analgesia (PCA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.
Study: NCT03289481
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet
Study: NCT03935217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Granules of placebo manufactured to mimic secnidazole
Study: NCT02311088
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02311088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02037776
Drug: Rikkunshito
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Oral administration of rikkunshito (2.5 g t.i.d) before meals for 8 weeks
Study: NCT02037776
Drug: Rikkunshito placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Oral administration of rikkunshito placebo (2.5 g t.i.d) before meals for 8 weeks
Study: NCT00503607
Drug: BLI-800
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002722
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002722
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03774290
Drug: PBF-680
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBF-680 is an adenosine A1 receptor antagonist
Study: NCT03774290
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gelatine capsule
Study: NCT02783820
Drug: MMV390048 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02783820
Drug: Placebo to match MMV390048 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02783820
Drug: MMV390048 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02783820
Drug: Placebo to match MMV390048 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02783820
Drug: MMV390048 120 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01265641
Drug: AZD1981, 2000mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose, tablets
Study: NCT01265641
Drug: AZD1981, 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose, tablets
Study: NCT01265641
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose, tablets
Study: NCT02936037
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: an inactive substance
Study: NCT01488955
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg oral once a day from day 0 for 3 days
Study: NCT00303927
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00730015
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, once daily
Study: NCT01821430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group will follow the same titration as the pregabalin group
Study: NCT00517842
Drug: ViNeuro
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00522743
Drug: growth hormone and gonadotropin-releasing hormone agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH \& GNRHa treatment
Study: NCT01854736
Drug: Grazax
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRAZAX
Study: NCT01347671
Drug: GRT6005
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25µg/day once daily
Study: NCT01347671
Drug: GRT6005
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 µg/day once daily
Study: NCT01347671
Drug: GRT6005
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 µg/day once daily
Study: NCT01347671
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT00517049
Drug: PRO95780
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT00385099
Drug: GW876008
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03831854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of oral Placebo
Study: NCT02438371
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03546816
Drug: Placebo Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablets
Study: NCT03169192
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intravenous injections once every 3 months
Study: NCT00285181
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04213677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo po qd. Additionally, participants will receive lifestyle modification and nutrition education.
Study: NCT01585441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule with no active ingredients to mimic finasteride
Study: NCT02231229
Drug: conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of a standard 4 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA); ethambutol (EMB or E)) until the results of DST are available.
Study: NCT03211728
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group receive placebo 150 mg 1 hour before surgery and 12 hours after initial dose.
Study: NCT03854019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.
Study: NCT00847821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as placebo capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
Study: NCT03416413
Drug: Foam sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of foam sclerosant into varicose vein tributaries
Study: NCT03792321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04563299
Drug: Dextenza 0.4Mg Ophthalmic Insert
Normalized name: Dextenza 0.4mg Ophthalmic Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive a sham dilation.
Study: NCT04563299
Drug: Prednisolone Acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).
Study: NCT01640171
Drug: Proparacaine Hydrochloride 0.5% Drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical drop given first to the treated eye.
Study: NCT02444728
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 1000mg intravenous infusion every month for 6 months
Study: NCT02444728
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After Cyclophosphamide treatment, Azathioprine 100mg once daily for 6 months
Study: NCT00665223
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules will be swallowed whole with water.
Study: NCT00338949
Drug: Switch
Normalized name: Universal Footswitch Covers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.
Study: NCT04539067
Drug: HHMG
Normalized name: Hydroxymethylglutaryl-CoA Reductase Inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction of ovulation from the 2nd day of cycle to 5th day then follow the diameter of follicle Use transvaginal ultrasound When diameter of follicle 18 to 22 patients receiving HMG
Study: NCT01976364
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 7.5-20 mg weekly
Study: NCT01976364
Drug: Placebo Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match active methotrexate orally once a week
Study: NCT02196077
Drug: BFF MDI 320/9.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
Study: NCT02196077
Drug: BFF MDI 160/9.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
Study: NCT02196077
Drug: BFF MDI 80/9.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
Study: NCT01613963
Drug: Immunosuppressive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with systemic corticosteroids and/or immunosuppressive agents Treatment with local corticosteroids and other drugs
Study: NCT02698306
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac Sodium
Study: NCT01619657
Drug: 6% Hypertonic Saline (HS), 4mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
Study: NCT01619657
Drug: 0.9% Isotonic Saline (IS), 4mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
Study: NCT02040987
Drug: AZD3293
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3293 oral solution - one single dose (low dose).
Study: NCT02040987
Drug: AZD3293
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3293 oral solution - one single dose (high dose).
Study: NCT02040987
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution - one single dose
Study: NCT02612506
Drug: Hepalatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: There are seven cohorts as follows 0.21mg, 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. Dose of 0.21mg is a pilot trial with no placebo. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
Study: NCT02612506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: There are six cohorts as follows 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
Study: NCT01266161
Drug: Ibuprofen 600 mg ER
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One 600 mg caplet dosed at 0, 12, 24 and 36 hours
Study: NCT01266161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo caplet dosed at times 0, 12, 24 and 36 hours
Study: NCT04092452
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00612222
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
Study: NCT00602186
Drug: tamsolusin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg /day
Study: NCT02831179
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02888379
Drug: TOP1288
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02888379
Drug: Placebo (for TOP1288)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02313337
Drug: Anesthesia induction(midazolam,fentanyl,propofol,atracurium)
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: After entering the operation room ,all cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
Study: NCT02313337
Drug: Anesthesia maintenance(midazolam,fentanyl,propofol,atracurium)
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: All cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
Study: NCT01267240
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00889967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily by inhalation for 28 days
Study: NCT01560195
Drug: Pegylated rhG-CSF: 100µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.
Study: NCT00115336
Drug: Intravenous Ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac
Study: NCT00115336
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen, taken orally
Study: NCT03096756
Drug: GC4702 dry powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg GC4702 mixed with approximately 270 mg of Prosolv 90 LM - SMCC (siliconized microcrystalline cellulose). Planned dose levels of GC4702 encapsulated dry powder formulation are 50, 100, and 150 mg
Study: NCT03096756
Drug: GC4702 lipid suspension
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: 112 mg GC4702 mixed with Miglyol 812 plus 0.5% by weight BHA plus 1% by weight of Aerosil 200. Planned dose levels of GC4702 encapsulated lipid suspension formulation are 112, 224, and 336, 448, and 560 mg
Study: NCT01965106
Drug: QPI-1007 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg QPI-1007 Injection
Study: NCT00095043
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002498
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002498
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002498
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002498
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01243060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-time dose of Placebo
Study: NCT02415920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
Study: NCT01536210
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1T/ Three times a day (tid) for 8 weeks, PO medication
Study: NCT00367913
Drug: Addition of clarithromycin to rifampicin and ethambutol
Normalized name: rifampicin, ethambutol and isoniazid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03880695
Drug: Anlotinib+ Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib : 12 mg, qd, po day 8-21 every 3 weeks Liposomal Doxorubicin: 50 mg/m2, day 1 every 3 weeks
Study: NCT00172081
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous injection with placebo
Study: NCT00172081
Drug: ALX1-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH (1-84) 100 mcg injected subcutaneously into the thigh or abdomen
Study: NCT04192513
Drug: J. lividum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Product
Study: NCT01760018
Drug: TIVA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: anesthesia is maintained with fresofol and remifentanil (TIVA group).
Study: NCT00885326
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).
Study: NCT02999711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00885326
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first.
Study: NCT02014883
Drug: GLUT1 DS
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no